Professional
Added to YB: 2024-11-01
Pitch date: 2024-09-30
ILMN [bullish]
Illumina, Inc.
+3.6%
current return
Author Info
No bio for this author
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Market Cap
$18.4B
Pitch Price
$130.18
Price Target
N/A
Dividend
N/A
EV/EBITDA
15.81
P/E
27.05
EV/Sales
4.60
Sector
Life Sciences Tools and Services
Category
growth
Baron Global Advantage Fund New Position: Illumina, Inc.
ILMN: Dominant NGS player (80% market share) poised for double-digit growth. <1% human genomes sequenced. TAM expansion via cost reduction (Novaseq X: $600 to $200). Full ecosystem (prep, sequencing, analytics) creates stickiness. Long-term growth potential in research/clinical diagnosis.
Read full article (1 min)